MOH lists abrocitinib on the medical assistance fund

The drug is used to treat atopic dermatitis.

The Ministry of Health (MOH) will list abrocitinib on its Medication Assistance Fund (MAF) on 1 March 2024.

Pfizer's abrocitinib is an oral tablet used to treat moderate-to-severe atopic dermatitis (AD). Eligible patients can now access alternative treatment options from public healthcare institutions.

Abrocitinib has been studied in the JADE clinical program, which involved over 3,800 adults and adolescents with moderate-to-severe AD.

Patients who received abrocitinib reported rapid relief from chronic itch and significant improvements in skin clearance.

“The subsidization of newer therapeutics will now improve accessibility to treatments for AD patients who rely on alternative treatments to manage their symptoms,” Ursula Soh, founder of Eczema Support Group Singapore (ESGS) said.

Follow the link for more news on

Pfizer

healthcare

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia